Pharmaceutical company Granules has posted a consolidated net profit at ₹163.63 crore for the quarter ended September, which is a nearly 71% increase over the ₹95.79 crore of the corresponding period of previous fiscal. At ₹858.12 crore (₹699.53 crore) revenue from operations was almost 23% higher, which the company said was “mainly on an account of new launches and increase in market share of existing products across the three verticals.”Chairman and managing director of Granules India Krishna Prasad Chigurupati said the second quarter performance, which was much better than committed guidance, “gives us confidence that we are on track to end the year’s performance as envisaged.” “Our long-term investments in backward and forward integration from APIs (active pharmaceutical ingredients) to FDs (finished dosages) helped us in delivering expected results as demonstrated by the 22% growth in our FDs revenue at ₹.430.1 crore this quarter,” he said.On API revenue, which was ₹254.7 crore up 17% YoY, Krishna Prasad added, it was driven by acquisition of new customers. The company received approvals for four finished dosage products during the quarter.The company has declared a second interim dividend of 25 paise per share of face value of ₹1 each for 2020-21.
A letter from the Editor
Dear subscriber,Thank you!Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.Suresh Nambath